Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2024; 15(7): 1562-1588
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1562
Network pharmacology and molecular dynamics study of the effect of the Astragalus-Coptis drug pair on diabetic kidney disease
Mo-Yan Zhang, Shu-Qin Zheng
Mo-Yan Zhang, Liaoning University of Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, Liaoning Province, China
Shu-Qin Zheng, Department of Endocrinology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China
Author contributions: Zhang MY and Zheng SQ participated in the study design and data collection; Zhang MY performed the data analysis; Zhang MY drafted the manuscript; and Zhang MY and Zheng SQ revised the manuscript; All the authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Qin Zheng, MSc, Associate Professor, Department of Endo-crinology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang 110032, Liaoning Province, China. qxjzsq@sina.com
Received: April 3, 2024
Revised: May 13, 2024
Accepted: May 29, 2024
Published online: July 15, 2024
Processing time: 95 Days and 17 Hours
Core Tip

Core Tip: Network pharmacology, molecular docking, and molecular dynamics simulation studies have demonstrated that diabetic kidney disease (DKD) treatment with the Astragalus-Coptis drug pair involves a diverse range of active ingredients, targets, and pathways. Additionally, quercetin has been found to exhibit strong affinity and binding stability with AKT serine/threonine kinase 1 and tumor necrosis factor, highlighting its potential therapeutic role in DKD. The findings of this study establish a robust theoretical basis for applying the Astragalus-Coptis drug pair in DKD treatment, and these results may provide a guiding framework for further experiments.